General

Cartherics is pleased to announce that Mathew Tiedemann has officially completed his PhD, a major milestone in an already impressive scientific journey! His thesis titled, ‘Developing a Clinically Translatable iPSC-derived Immunotherapy’ focused on designing clinically relevant methods to create billions of gene-edited blood cells from stem cells to better detect and destroy ovarian cancer.

Mat’s key […]

In the competitive biotech landscape, groundbreaking science alone isn’t enough. As highlighted in a recent article by Dynamic Business, Cartherics’ strategic appointment of U.S. biotech executive Laurence Nore underscores the critical importance of navigating the complexity of healthcare markets. Laurence emphasises that many promising biotech firms falter not due to flawed science but because they […]

Cartherics’ appointment of Laurence Nore underscores a growing trend with global implications. 

As global demand for biotechnology products and services continues to grow, innovation in the industry is becoming increasingly globalised. Cartherics Pty Ltd, a Melbourne-based biotech company pioneering cell-based immunotherapies, recently announced the appointment of U.S. life sciences executive Laurence Nore to […]

Today on World Ovarian Cancer Day, we are proud to share the powerful story of Heather Hawkins – ovarian cancer survivor, global marathon runner, patient advocate, and a valued Board Advisor at Cartherics.

After being diagnosed with ovarian cancer in 2007, Heather transformed her experience into a mission of awareness, action, and hope. Her survivorship, combined […]